Search results for: Market Access

Part 2: 2010 Lecture on US Health Reform

27 July 2010

…delivery and payment changes are to be put into effect.  ‘Health insurance exchanges’ are an important part of this.  These are state-level ‘marketplaces’ of health insurance plans, with a range…

An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

29 July 2015

…which led to the introduction of Patient Access Schemes in the 2009 PPRS.  The question of whether NICE and/or the Department of Health (DH) should be a price taker or…

Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations

25 August 2015

…is likely to decrease when other drugs with similar therapeutic effects enter the market. Also, when the patent of the drug expires, generic versions will most likely be launched and…

OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology

14 July 2016

…in improving length of life. However, measuring OS requires a large number of patients and long follow-up periods. This considerably increases the cost of development and delays patients’ access to…

Presentation at the NHS Global Health Volunteering Group Meeting: “The Value of International Volunteering and Placements to the NHS”

…and volunteering to the NHS. Dr Bernarda Zamora presented the research findings at the NHS Global Health Volunteering Group meeting held in London on 4th September 2017 (access the slides…

An Insurance Framework for Funding New Antibiotics

22 September 2017

…In the USA and Europe, financial incentives have focussed on supporting R&D through “push” incentives, reducing regulatory burden, and extending market exclusivity. The authors use resistance data to estimate global…

Alan Maynard – Alas No More

5 February 2018

…clinical professions, misdirected training in public health management skills, redirecting policy focus from inputs to outputs, the need for rational rationing, competition and choice in the NHS, avoiding misplaced market…

The Impact of New Medicines in the NHS: 70 Years of Innovation

14 August 2018

…and pharmaceutical interventions. Over this period, many new medicines have been developed in the UK and overseas, to which the NHS has provided patients access. But which of these new…

Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?

20 December 2018

…digital technology, we are collecting more and more data in real-time, through which we can discern patterns in behaviour and begin to predict events. The health care market is no…